Physician profile
James Holzhauer
NPI 1245224872
$831.29
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $203 · 2021: $336 · 2022: $85.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $285.73 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $215.43 | 2019-2020 | |
| Astellas Pharma US INC | $85.00 | 2022 | |
| Lilly USA, LLC | $77.93 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.47 | 2020 | |
| Pfizer INC. | $40.41 | 2020 | |
| Allergan, INC. | $24.47 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.17 | 2020-2021 | |
| Lupin INC. | $17.78 | 2020 | |
| Eisai INC. | $11.90 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Holzhauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.